The year 2024 marked a regulatory and industrial turning point for the healthcare sector in France and Europe. The dynamics that currently shape medical and pharmaceutical news are no longer solely about technological innovation: they involve the supply chain of medications, the regulation of artificial intelligence applied to medical devices, and the financial sustainability of new treatments.
AI Act and medical devices: what the European regulation changes concretely
The adoption of the regulation (EU) 2024/1689, published in the Official Journal of the European Union on July 12, 2024, places medical AI systems in the category of high-risk applications. This classification is not cosmetic: it imposes specific obligations on manufacturers and software publishers regarding risk management, quality of training data, traceability of algorithmic decisions, and human oversight.
For players in the pharmaceutical and medical device markets, the direct consequence pertains to compliance files. Every diagnostic or prescription support system must document its algorithmic life cycle, from data collection to model updates. Regulatory affairs teams see their scope significantly broadened.
We observe that most articles on health news and medical technologies in 2024 focus on the promises of generative AI, without addressing this operational regulatory layer. Pharmacy professionals, hospital pharmacists, and developers of digital health solutions need this framework to anticipate the necessary investments in compliance. Monitoring these topics involves specialized sources like doctinews.fr, which regularly covers the interface between regulation and pharmaceutical practice.
Drug shortages and supply chain resilience in France
Managing drug shortages has become a structural axis of European pharmaceutical policy. The European Commission published a proposal for a regulation in April 2023 establishing new procedures for human medicines, and the Critical Medicines Alliance delivered a strategic report in February 2024. These two texts aim to secure the supply of health products deemed critical.
In France, the ANSM (National Agency for the Safety of Medicines) manages stock shortage reports in real-time. Recurring tensions on certain specialized production lines remind us of the persistent fragility of the supply chain.
The development of local production capacities, diversification of active ingredient suppliers, and the establishment of strategic stocks are among the activated levers. For community pharmacies, these tensions translate into an increased management burden and the need to offer validated therapeutic alternatives.
- Strengthened reporting obligation for laboratories in case of risk of shortages, with shorter notification deadlines imposed by the European regulation currently being finalized.
- Establishment of the Critical Medicines Alliance at the European level, responsible for identifying strategic molecules and coordinating industrial responses.
- Strengthening the role of the ANSM in monitoring availability, with regular publication of lists of products under tension on its dedicated portal.
GLP-1 agonists: access, supply, and long-term management
Semiaglutide and tirzepatide dominated pharmaceutical news in 2024, well beyond the initial scope of type 2 diabetes. The extension of indications to obesity has caused global supply tensions and reignited the debate on the sustainability of healthcare systems.
Off-label demand has amplified stock shortages, penalizing diabetic patients for whom these treatments were initially designed. We recommend that pharmacists and prescribers clearly distinguish validated indications from off-label uses in their daily practice.
The revenue generated by these molecules is reshaping the global pharmaceutical market. Several laboratories are accelerating the development of competing molecules, which should gradually ease supply. The question of long-term management remains open: the cumulative cost of chronic treatment with GLP-1 agonists heavily burdens health insurance budgets.
Antimicrobial resistance and RSV vaccines: two public health fronts
The fight against antimicrobial resistance (AMR) is intensifying globally. Several institutional reports published in 2024 highlight the urgency of rationalizing antibiotic prescriptions and developing new agents. In France, the ANSM closely supervises the pharmacovigilance of new therapeutic approaches.
On the front of respiratory infections, vaccines against respiratory syncytial virus (RSV) represent a major advancement. Initial pharmacovigilance feedback on preventive treatments deployed allows for real-time adjustments to recommendations.
- AMR requires coordination between prescribers, pharmacists, and microbiology laboratories to guide treatments based on targeted antibiograms.
- The deployment of preventive treatments against RSV in the general population involves specific logistics, with conservation and traceability constraints managed in pharmacies and maternity wards.
The medical and pharmaceutical news of 2024 is characterized by this intertwining of therapeutic innovation, regulatory constraints, and supply challenges. Healthcare professionals who closely follow these developments, whether regarding compliance with the AI Act, managing shortages, or monitoring new treatments, have a real operational advantage in a rapidly changing market.
